熱門資訊> 正文
精密生物科学GAAP每股收益为-2.13美元,相差0.56美元
2025-08-07 19:56
- Precision BioSciences press release (NASDAQ:DTIL): Q2 GAAP EPS of -$2.13 misses by $0.56.
- Extended expected cash runway to the second half of 2027 providing more than two years of operating cash
More on Precision BioSciences
- Precision BioSciences Q2 2025 Earnings Preview
- Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%
- Seeking Alpha’s Quant Rating on Precision BioSciences
- Historical earnings data for Precision BioSciences
- Financial information for Precision BioSciences
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。